Cyclohexyl-griselimycin Is Active against Mycobacterium abscessus in Mice

Cyclohexyl-griselimycin is a preclinical candidate for use against tuberculosis (TB). Here, we show that this oral cyclodepsipeptide is also active against the intrinsically drug-resistant nontuberculous mycobacterium Mycobacterium abscessus in vitro and in a mouse model of infection. This adds a no...

Descripción completa

Detalles Bibliográficos
Autores principales: Aragaw, Wassihun Wedajo, Roubert, Christine, Fontaine, Evelyne, Lagrange, Sophie, Zimmerman, Matthew D., Dartois, Véronique, Gengenbacher, Martin, Dick, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8765428/
https://www.ncbi.nlm.nih.gov/pubmed/34723632
http://dx.doi.org/10.1128/AAC.01400-21
Descripción
Sumario:Cyclohexyl-griselimycin is a preclinical candidate for use against tuberculosis (TB). Here, we show that this oral cyclodepsipeptide is also active against the intrinsically drug-resistant nontuberculous mycobacterium Mycobacterium abscessus in vitro and in a mouse model of infection. This adds a novel advanced lead compound to the M. abscessus drug pipeline and supports a strategy of screening chemical matter generated in TB drug discovery efforts to fast-track the discovery of novel antibiotics against M. abscessus.

Ejemplares similares